Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo. 

PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.

One of the event's primary takeaways was that interventional cardiology does still attract a healthy number of trainees. However, SCAI sees several ways the specialty can improve to be even more appealing in the future.